WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.:
- Do you own shares of Ocera Therapeutics, Inc. (NASDAQ CM: OCRX)?
- Did you purchase any of your shares prior to November 2, 2017?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ocera Therapeutics, Inc. (“Ocera” or the “Company”) (NASDAQ CM: OCRX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Mallinckrodt plc (“Mallinckrodt”) (NYSE: MNK). Under the terms of the agreement, shareholders of Ocera will receive $1.52 per share plus one Contingent Value Right to receive one or more payments in cash of up to $2.58 per share, based on the successful completion of certain development and sales milestones.
If you own common stock of Ocera and purchased any shares before November 2, 2017, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242, or by e-mail at firstname.lastname@example.org.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.